Nyxoah SA (NYXH) News & Sentiment

REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year  202 4 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 1 3 , 2024 , 7 : 0 0 am CET / 2 : 0 0 am ET – Nyxoah SA ( Euronext Brussels/Nasdaq : NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation , today reported financial and operating results for the fourth quarter and financial year 2024 .   Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

Nyxoah to Participate in the Oppenheimer 35 th Annual Healthcare MedTech & Services Conference

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy  in the Middle East First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), January 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On January 16, 2025, Nyxoah received a transparency notification from BlackRock, Inc. and related persons.

Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment, with FDA approval expected in Q1 2025 acting as a potential catalyst for shares. Nyxoah, founded by Robert Taub, is led by Olivier Taelman and focuses on the Genio implant, which offers a less intrusive alternative to CPAP and Inspire Therapy. Despite a high burn rate, Nyxoah has sufficient cash reserves to last until 2026, with U.S. market entry expected to significantly boost revenue post-FDA approval.

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On December 19, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons.

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold.